다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc (REGN) 뉴스

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:REGN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/15	05:26	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/14	05:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/13	06:04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/13	05:10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/13	05:10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/11	20:00	GlobeNewswire Inc.	Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/11	05:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/08	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/07	05:12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/06	05:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/06	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/06	03:24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/06/04	05:36	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/31	14:05	GlobeNewswire Inc.	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/31	14:00	GlobeNewswire Inc.	Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/30	05:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/29	20:15	PR Newswire (US)	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/29	05:29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/24	06:03	GlobeNewswire Inc.	Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/23	05:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/22	05:10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/21	03:15	GlobeNewswire Inc.	Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	06:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	05:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/18	02:45	GlobeNewswire Inc.	More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/16	07:10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/15	05:21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/13	14:00	GlobeNewswire Inc.	Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/08	19:00	GlobeNewswire Inc.	Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	NASDAQ:REGN	Regeneron Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:REGN

1 2 3 4 5 6 7 8 9 10 다음 >>

Bank of America

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

Verizon Communications

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관